Judge Rules Collegium Pharmaceutical Inc. Does Not Infringe Two OxyContin Patents

October 1, 2018

A Massachusetts federal judge recently ruled that Robins Kaplan client Collegium Pharmaceutical Inc. did not infringe upon two of Purdue Pharma LP’s OxyContin-related patents. The ruling represents a significant victory for Collegium and its two-year-old drug, Xtampza XR.

Law360 covered the ruling in a recent article:
Xtampza Not Infringing 2 OxyContin Patents, Judge Says

All Content © 2018, Portfolio Media, Inc.

Jake M. Holdreith


Managing Partner, Minneapolis Office
Member of Executive Board

Oren D. Langer


Managing Partner, New York Office

Back to Top